Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 2,625 shares at $10.73 ($28K) on 2026-06-04, disclosed to the SEC on 2026-06-08.
Scheduled sale ($28k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |
| KROS | SELL | 2021-10-21 | $598K | — | Filing → |